ROSWELL PARK CANCER INSTITUTE

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Bortezomib, Doxorubicin Hydrochloride Liposome, and Rituximab in Treating Patients With Diffuse Large B-Cell Lymphoma That Has Relapsed or Not Responded to Treatment

Phase 2

Terminated

Conditions: Lymphoma

First Posted Date: 2009-02-26

Last Posted Date: 2014-07-21

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 9

Registration Number: NCT00851552

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Sunitinib and Surgery in Treating Patients With Localized or Metastatic Kidney Cancer

Not Applicable

Completed

Conditions: Kidney Cancer

Interventions: Drug: sunitinib malate
Procedure: neoadjuvant therapy
Procedure: therapeutic conventional surgery

First Posted Date: 2009-02-23

Last Posted Date: 2015-02-06

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 20

Registration Number: NCT00849186

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Radiation Therapy in Treating Patients With Stage I or Stage II Non-Small Cell Lung Cancer

Phase 2

Completed

Conditions: Lung Cancer

Interventions: Radiation: Arm 1 stereotactic body radiation therapy
Radiation: Arm II stereotactic body radiation therapy

First Posted Date: 2009-02-13

Last Posted Date: 2021-06-15

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 98

Registration Number: NCT00843726

Locations: 🇺🇸
SUNY Upstate Medical University, Syracuse, New York, United States
🇺🇸
Cleveland Clinic, Cleveland, Ohio, United States
🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

An Alternative Dosing Schedule of Varenicline for Smoking Cessation

Phase 2

Completed

Conditions: Smoking Cessation

Interventions: Drug: placebo
Drug: varenicline

First Posted Date: 2009-02-04

Last Posted Date: 2017-05-30

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 60

Registration Number: NCT00835900

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Clofarabine and Daunorubicin in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia

Phase 2

Terminated

Conditions: Leukemia

Interventions: Drug: clofarabine
Drug: daunorubicin hydrochloride
Genetic: cytogenetic analysis
Genetic: protein expression analysis
Other: immunologic technique
Other: pharmacological study

First Posted Date: 2008-12-24

Last Posted Date: 2016-08-17

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 21

Registration Number: NCT00814164

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Magnetic Resonance Imaging in Detecting Cancer Progression in Patients With Early Stage Prostate Cancer Undergoing Active Surveillance

Not Applicable

Withdrawn

Conditions: Prostate Cancer

First Posted Date: 2008-11-24

Last Posted Date: 2013-07-25

Lead Sponsor: Roswell Park Cancer Institute

Registration Number: NCT00796874

Flaxseed in Preventing Breast Cancer in Premenopausal Women at Risk of Developing Breast Cancer

Not Applicable

Terminated

Conditions: Breast Cancer
Precancerous Condition

Interventions: Other: No Intervention
Dietary Supplement: Ground Flaxseed

First Posted Date: 2008-11-21

Last Posted Date: 2016-06-03

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 20

Registration Number: NCT00794989

Locations: 🇺🇸
Roswell Cancer Park Institute, Buffalo, New York, United States
🇺🇸
University of Chicago Medicine, Chicago, Illinois, United States

Selenomethionine and Finasteride Before Surgery or Radiation Therapy in Treating Patients With Stage I or Stage II Prostate Cancer

Phase 2

Completed

Conditions: Prostate Cancer

Interventions: Dietary Supplement: selenomethionine
Other: placebo
Drug: finasteride

First Posted Date: 2008-08-18

Last Posted Date: 2023-10-02

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 55

Registration Number: NCT00736645

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Selenomethionine in Treating Patients Undergoing Surgery or Internal Radiation Therapy for Stage I or Stage II Prostate Cancer

Phase 2

Withdrawn

Conditions: Prostate Cancer

Interventions: Dietary Supplement: selenomethionine
Other: placebo

First Posted Date: 2008-08-15

Last Posted Date: 2012-02-06

Lead Sponsor: Roswell Park Cancer Institute

Registration Number: NCT00736164

Fludeoxyglucose F 18 in Detecting Lymph Node Metastasis in Patients With Stage I or Stage II Non-Small Cell Lung Cancer That Can Be Removed by Surgery

Not Applicable

Completed

Conditions: Lung Cancer

First Posted Date: 2008-08-12

Last Posted Date: 2017-10-18

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 100

Registration Number: NCT00732563

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy